January 6, 2023
Via: PharmaphorumThe acquisition adds multiple clinical and pre-clinical immunology assets to the company’s own immunology pipeline – led by izokibep, a small therapeutic protein inhibitor of interleukin-17A (IL-17A), designed to overcome the limitations of monoclonal antibodies – and includes a potentially […]
March 30, 2023
March 28, 2023
March 23, 2023
March 16, 2023